IDO1 and type 1 diabetes mellitus: In type 1 diabetes, IL-27-MSC may activate IDO to expand Tregs in pancreatic lymph nodes, thereby inhibiting β-cell destruction by effector T cells, with TSG-6 potentially mitigating islet inflammation [58].